- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03010150
Bloedonderzoek en vragenlijsten bij het bestuderen van de naleving van preventieve slikoefeningen bij deelnemers met uitgezaaide hoofd-halskanker
Modelleren van therapietrouw bij preventieve slikoefeningen bij hoofd-halskanker
This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease. Using blood tests to study cytokines (proteins related to the immune system) may help doctors learn if certain levels of cytokines affect whether or not side effects occur and if they put participants at risk for future disease. Questionnaires may help doctors learn about the reasons head and neck cancer participants may or may not follow the swallowing exercises that they are asked to perform after receiving radiation treatments.
Studie Overzicht
Toestand
Conditie
- Klinisch stadium III HPV-gemedieerd (p16-positief) orofarynxcarcinoom AJCC v8
- Stadium III hypofarynxcarcinoom AJCC v8
- Stadium III Larynxcarcinoom AJCC v8
- Stadium III Orofaryngeaal (p16-negatief) carcinoom AJCC v8
- Stadium IV hypofarynxcarcinoom AJCC v8
- Stadium IV larynxkanker AJCC v8
- Stadium IV orofaryngeaal (p16-negatief) carcinoom AJCC v8
- Klinisch stadium I HPV-gemedieerd (p16-positief) orofarynxcarcinoom AJCC v8
- Klinisch stadium II HPV-gemedieerd (p16-positief) orofarynxcarcinoom AJCC v8
- Pathologisch stadium I HPV-gemedieerd (p16-positief) orofarynxcarcinoom AJCC v8
- Pathologisch stadium II HPV-gemedieerd (p16-positief) orofarynxcarcinoom AJCC v8
- Stadium IV Nasofarynxcarcinoom AJCC v8
- Pathologisch stadium III HPV-gemedieerd (p16-positief) orofarynxcarcinoom AJCC v8
- Stadium IVA Nasofarynxcarcinoom AJCC v8
- Stadium IVB Nasofarynxcarcinoom AJCC v8
- Stadium IVA hypofarynxcarcinoom AJCC v8
- Stadium IVA Larynxcarcinoom AJCC v8
- Stadium IVA Orofaryngeaal (p16-negatief) carcinoom AJCC v8
- Stadium IVB Hypofarynxcarcinoom AJCC v8
- Stadium IVB Larynxkanker AJCC v8
- Stadium IVB Orofaryngeaal (p16-negatief) carcinoom AJCC v8
- Gemetastaseerd hoofd-halscarcinoom
- Carcinoom van onbekende primaire
- Gemetastaseerd maligne neoplasma in de baarmoederhals
- Stadium I hypofarynxcarcinoom AJCC v8
- Stadium I nasofarynxcarcinoom AJCC v8
- Stadium II hypofarynxcarcinoom AJCC v8
- Stadium II Larynxcarcinoom AJCC v8
- Stadium II Nasofarynxcarcinoom AJCC v8
- Stadium II orofaryngeaal (p16-negatief) carcinoom AJCC v8
- Stadium III Nasofarynxcarcinoom AJCC v8
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To determine whether illness perceptions significantly predict adherence to swallowing exercises at 6 months after the end of radiation.
II. To determine whether sickness behaviors (depression, fatigue, pain)'s effect on illness perceptions are mediated by pro-inflammatory cytokines.
III. To determine whether social support moderates the impact of coping on appraisal of coping.
SECONDARY OBJECTIVES:
I. As a secondary aim, to determine the feasibility and utility of cardiac impedance pre-ejection period measurement as a corollary measure for depression and distress.
II. As a secondary aim, to identify potential genetic markers for swallowing dysfunction which has developed by the 6-month follow-up.
OUTLINE:
Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
After completion of study, participants are followed up periodically for up to 2 years.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- M D Anderson Cancer Center
-
Contact:
- Eileen H. Shinn
- Telefoonnummer: 713-745-0870
-
Hoofdonderzoeker:
- Eileen H. Shinn
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Participants with head and neck cancer
Beschrijving
Inclusion Criteria:
- Are dispositioned to receive radiation with curative intent for nasopharyngeal, oropharyngeal, hypopharyngeal, laryngeal, or an unknown primary cancer with cervical metastases
- Are stage II-IVb for non- human papillomavirus (HPV)- related oropharyngeal cancer
- Have HPV- related oropharynx cancer that is T1, have nodal involvement with no distant metastasis or have HPV- related oropharynx cancer that is at least T2 with no distant metastasis
- Are stage II-IVb for laryngeal cancer
- Are stage I-IVb for hypopharyngeal
- Are stage I-IVb for nasopharyngeal cancer
- Have stage I-III unknown primary cancer with cervical
Exclusion Criteria:
- Have other cancer diagnoses, except non-melanoma skin cancer
- Had treatment for previous head and neck cancer or radiation to the head and neck
- Have a history of previous head and neck surgery (excluding biopsy and/or tonsillectomy and/or tracheotomy)
- Have a current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g., dysphagia due to underlying neurogenic disorder)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Observational (blood tests, questionnaires)
Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection. |
Ancillary studies Provide blood samples |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adherence to swallowing exercises
Tijdsspanne: Up to 6 months
|
The primary analytic approach is to use linear mixed models to determine whether illness perceptions significantly predict adherence 6 months. The study will estimate and test the illness perception subscale scores' relationship to adherence using a linear mixed model. In the model, the dependent variable is the patient's self-reported adherence score and independent variables include illness perception, follow-up assessment time point and other covariates such as demographic and medical variables, depression, pain, fatigue, emotional coping, objective coping, appraisal of coping, stress, and lack of social well-being. |
Up to 6 months
|
|
Illness perceptions
Tijdsspanne: Up to 6 months
|
The study's statistical tool is mediation analysis: the independent variables are the sickness behaviors (depression, fatigue, pain); the mediators are the cytokine levels, and the outcome variable is illness perception. The study will test the mediator effects based on the product of coefficients method, rather than the classical Baron & Kenny causal steps tests, since the former approach has better statistical power. The study will conduct both single-mediator analysis for each of the mediators, and multiple-mediator analysis with all mediators in the mediating process |
Up to 6 months
|
|
Effect of social support on coping
Tijdsspanne: Up to 6 months
|
The moderating effect of social support on coping and appraisal of coping is the statistical equivalent of testing the two-way interaction between these variables and the social support variable. Multivariate linear regression will be used, in which the dependent variable is appraisal of coping at 6 months follow-up, and independent variables include the emotion-focused coping and action-focused sub scales, social support, and their two-way interactions. In the regression, the study will control for baseline variables. In addition, we will also apply the linear mixed model to investigate the moderating effect of these variables longitudinally. The mixed model naturally accounts for the correlation of repeated measures at baseline and 6 months follow-up. |
Up to 6 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Eileen H Shinn, M.D. Anderson Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Stomatognatische ziekten
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Hoofd- en nekneoplasmata
- Neoplasmata, glandulair en epitheel
- Neoplasmata van de luchtwegen
- Neoplastische processen
- KNO-ziekten
- Faryngeale neoplasmata
- Otorinolaryngologische neoplasmata
- Nasofaryngeale ziekten
- Faryngeale ziekten
- Laryngeale ziekten
- Neoplasma metastase
- Nasofaryngeale neoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Nasofarynxcarcinoom
- Carcinoom
- Laryngeale neoplasmata
- Orofaryngeale neoplasmata
- Neoplasmata, onbekend primair
- Hypofaryngeale neoplasmata
Andere studie-ID-nummers
- 2016-0597
- 2016-0597 (Andere identificatie: M D Anderson Cancer Center)
- NCI-2018-01260 (Register-ID: CTRP (Clinical Trial Reporting Program))
- R21DE019954 (Subsidie/contract van de Amerikaanse NIH)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .